List of Akten drug patents

Akten is owned by Akorn.

Akten contains Lidocaine Hydrochloride.

Akten has a total of 1 drug patent out of which 0 drug patents have expired.

Akten was authorised for market use on 07 October, 2008.

Akten is available in gel;ophthalmic dosage forms.

Akten can be used as method of inducing topical anesthesia in the eye.

The generics of Akten are possible to be released after 24 July, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8759401 AKORN Aqueous gel formulation and method for inducing topical anesthesia
Jul, 2026

(3 years from now)

Drugs and Companies using LIDOCAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 October, 2008

Treatment: Method of inducing topical anesthesia in the eye


More Information on Dosage

AKTEN family patents


United States


European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in